Key result
Second-line obinutuzumab and glofitamab resolve coronary compression and improve LVEF to 56% in a single case.
Why the study?
Primary cardiac lymphoma is extremely rare and presents with varied symptoms, requiring multimodal imaging and tissue confirmation for accurate diagnosis.
Population
62-year-old male with a history of B-cell lymphoma
Design
Case report
Authors
Loading...
May support targeted immunochemotherapy for rare cardiac lymphoma with coronary compression; leaves open prospective validation before wider adoption.
Case Report (n=1)
Cardiac lymphoma should be considered in the differential diagnosis of recurrent pericardial effusion, unexplained ventricular dysfunction, or atypical coronary stenoses in patients with a history of lymphoproliferative disease, as targeted immunochemotherapy can induce complete functional cardiac recovery.
Sciarretta et al. (2026) conducted a case report in B-cell non-Hodgkin lymphoma with cardiac involvement (n=1). Obinutuzumab and Glofitamab was evaluated on Cardiac functional recovery and mass regression. Second-line targeted immunochemotherapy with Obinutuzumab and Glofitamab induced progressive mass regression, improved LVEF from 38% to 56%, and completely resolved extrinsic coronary compression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: